Translating mRNA
Educational Webinar Series
The Pfizer Vaccines US Medical Affairs Team invites you to attend
an educational webinar series titled Translating mRNA which is
focused on providing education on COVID-19 and vaccination. The
webinar series is designed to communicate scientific information
which may include recent study results to inform healthcare
providers regarding Pfizer and BioNTech’s COVID-19 vaccines.
The webinar series will include a live question-and-answer session
with Pfizer medical experts.
We will soon be hosting a Translating mRNA session.
If you would like to be notified when the registration opens for the next webinar click here
To view recordings of previous Translating mRNA webinars and other medical resources click here or here. Intended Audience: US healthcare professionals including but not limited to physicians, nurse practitioners, pharmacists, and physician assistants. Continuing medical education credit is NOT associated with this event.Indication:
COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for
active immunization to prevent coronavirus disease 2019 (COVID-19)
caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) in individuals 12 years of age and older.
Emergency Use Authorization:
Emergency uses of COVID-19 vaccines from BioNTech and Pfizer,
including Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula),
have not been approved or licensed by FDA, but have been
authorized by FDA, under an Emergency Use Authorization (EUA) to
prevent Coronavirus Disease 2019 (COVID-19) in individuals 6
months of age and older. Emergency uses are only authorized for
the duration of the declaration that circumstances exist
justifying the authorization of emergency use of the medical
products under Section 564(b)(1) of the FD&C Act unless the
declaration is terminated or authorization revoked sooner.
For most recent US Full Prescribing Information and Fact Sheets,
please visit
www.cvdvaccine-us.com